Abstract
While cisplatin has proven effective as a antitumor agent in treating a variety of forms of cancer, such as testicular and ovarian carcinomas,1 a substantial effort has been made in new drug development programs to improve the therapeutic properties of platinum-based antitumor agents.2 Major objectives of research in this area include the development of new agents that have an improved spectrum of activity and are more effective and less toxic than cisplatin.3 To date these efforts have produced a number of new compounds that show good activity in various animal tumor screens.4 While recent clinical studies show that some second-generation analogs, such as carboplatin, cis-[Pt(NH3)2-(1,1 -cyclobutanedicarboxylate)]5, are less toxic than cisplatin, the search for new agents that display a significantly different spectrum of activity is continuing in laboratories worldwide.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Loehrer, P.J.; Einhorn, L.H. Ann. Intern Med. 1984,100,704.
Hacker, M.P.; Douple, E.B.; Krakoff, I.H., Eds.; “Platinum Coordination Complexes in Cancer Chemotherapy”; Martinus-Nijhoff: Boston, 1984.
Prestayko, A.E.; Crooke, S.T.; Carter, S.K., Eds.; “Cis-platin, Status and New Developments”; Academic Press: New York, 1980.
Lippard, S.J., Ed.; “Platinum, Gold and Other Metal Chemo-therapeutic Agents”; American Chemical Society: Washington, D.C., 1983; ACS Symp. Ser. No. 209.
McBrien, D.C.H.; Slater, T.F., Eds.; “Biochemical Mechanism of Platinum Antitumor Drugs”; IRL Press, Washington, DC, 1986.
Carter, S.K. In ref 2a, p 359.
Rose, W.C.; Bradner, W.T. In ref 2b, p. 229.
Egorin, M.J.; Van Echo, D.A.; Olman, E.A.; Whitacre, M.Y.; Forrest, A.; Aisner, J. Cancer Res. 1985,45,6502.
Calvert, A.H. In ref 2d, p 307.
Barnard, C.F.J.; Cleare, M.J.; Hydes, P.C. Chem. Brit. 1986, 22,1001.
Appleton, T.G.; Hall, J.R.; Ralph, S.F. Inorg. Chem. 1985, 24,4685.
Hollis, L.S.; Stern, E.W.; Amundsen, A.R.; Miller, A.V.; Doran, S.L. J. Am. Chem. Soc. 1987,109,3596.
Hollis, L.S.; Amundsen, A.R.; Stern, E.W. J. Am. Chem. Soc. 1985,107,274.
Crystallographic data. [Pt(S,S-dach) (C2,O5-Asc)] 5H2O crystallizes in the orthorhombic space group P212121 with the following cell parameters: a = 12.366(1), b = 22.371(3), c = 6.782(1) Å, V = 1876.3 Å3, Z = 4. The structure was solved by using standard Patterson and Fourier methods using 1943 reflections (2θ < 50°) collected on an Enraf-Nonius CAD-4F diffractometer. Refinement of the absorption corrected data, with all atoms (execpt H) assigned anisotropic thermal parameters converged at Rf = 0.033 and Rw = 0.045. Full details will be reported at a later date.
Basch, H.; Krauss, M.; Stevens, W.J.; Inorg. Chem. 1986,25, 4777.
Hollis, L.S.; Stern, E.W. Inorg. Chem. Submitted for publication.
Farrel, N. In ref 2c, p 279.
Crystallographic data. [Pt(R,R-dach)(C2-CHD)(O1-CHD)] (16) crystallizes in the space group PI with the following cell parameters: a = 10.225(1), b = 11.841(1), c = 9.387(1) Å, α = 112.15(1)°, β = 106.15(1)°, γ = 87.91(1)°, V = 1008.2 Å3, Z = 2. The structure was solved by using standard Patterson and Fourier methods using 4475 unique reflections (20 < 54°). Refinement of the absorption corrected data, with all atoms, except Pt, N and O, assigned isotropic thermal parameters converged at Rf = 0.023 and Rw = 0.025. Full details will be reported at a later date.
Crystallographic data. [Pt(en)(C3,O8-CPD2)] (19) crystallizes in the triclinic space group P1 with the following cell parameters: a = 10.528(2), b = 11.533(2), c = 7.728(1) Å,α= 89.91(1)°, β= 106.25(1)°, γ = 70.92(1)°, V = 841.0 Å3, Z = 2. The structure was solved as in ref 9, using 2098 reflections (2θ < 45°). Refinement of the absorption corrected data, with all atoms (except H) assigned anisotropic thermal parameters converged at Rf = 0.019 and Rw = 0.029. Full details will be reported at a later date.
The test protocol for the S180a screen is described in ref 16. Compounds were administered on day one using 6 mice/dose; an ILS > 50% indicates activity. The reported dose is that which gave the the best %ILS. The test protocol for the L1210 screen is given in ref 17. Compounds were administered on day one and an ILS > 25% indicates activity. Surviving mice were counted as dying on the day of evaluation.
Amundsen, A.R.; Stern, E.W. U.S. Patent 4 457 926, 1984.
Rose, W.C.; Schurig, J.E.; Huftalen, J.B.; Bradner, W.T. Cancer Treat. Rep. 1982,66,135.
Data not shown.
Abbreviations: CHD, 1,3-cyclohexanedione; MCHD, 5-methyl-CHD; DCHD, 5,5-dimethyl-CHD; CPD, 1,3-cyclopentanedione; CPD2, CPD dimer.
Kidani, Y.; Inagaki, K.; Iigo, M.; Hoshi, A.; Kuretani, K. J. Med. Chem. 1978,21,1315.
Kidiani, Y.; Inagaki, K.; Saito, R.; Tsukagoshi, S. Wadley Med. Bull. 1977,7,197.
Saito, R.; Kidani, Y. Bull. Chem. Soc. Jpn. 1986,59,1689.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Hollis, S.L., Doran, S.L., Amundsen, A.R., Stern, E.W. (1988). Platinum-Based Organometallic Complexes of Vitamin C and Related Analogs as Antitumor Agents. In: Nicolini, M. (eds) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Developments in Oncology, vol 54. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1717-3_62
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1717-3_62
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8967-8
Online ISBN: 978-1-4613-1717-3
eBook Packages: Springer Book Archive